Targeting Rac1 for the prevention of atherosclerosis among U.S. Veterans with inflammatory bowel disease. (31st December 2022)

• Record Type: Journal Article
• Authors: Sutton, S. Scott; Magagnoli, Joseph; Cummings, Tammy H.; Hardin, James W.
• Is Part Of: Small GTPases. Volume 13:Number 1(2022)
• Page Start: 205
• Page End: 210
• Publication Date: 2022-12-31
• Subjects: Rac1 -- thiopurines -- atherosclerosis -- cohort -- inflammatory bowel disease; Guanosine triphosphatase -- Periodicals; Guanosine triphosphatase; Periodicals; 572.793
• DOI: 10.1080/21541248.2021.1954863
• Languages: English
• ISSNs: 2154-1256

Abstract

ABSTRACT: Evidence suggests that Ras-related C3 botulinum toxin substrate 1 (Rac1) might be a target in atherosclerotic disease (AD). We hypothesize that due to their ability to inhibit Rac1, thiopurines are associated with a lower risk of AD. We fit a time-dependent cox proportional hazards model estimating the hazard of AD among a national cohort of US veterans with inflammatory bowel disease. Patients exposed to thiopurines had a 7.5% lower risk of AD (HR = 0.925; 95% CI = (0.87–0.984)) compared to controls. The propensity score weighted analysis reveals thiopurine exposure reduces the risk of AD by 6.6% (HR = 0.934; 95% CI = (0.896–0.975)), compared to controls. Further exploration and evaluation of Rac1 inhibition as a target for AD is warranted.